Skip to main content
Skip to footer

  • WHITE PAPER

Pharma Firms Switch Gears from Response to Transformation

Debashis Ghosh

President of Life Sciences, Healthcare, Public Services and Energy Business Group, TCS

Sanjeev Sachdeva

CTO and Global Head Advisory Services – Life Sciences, TCS

You have these already downloaded

We have sent you a copy of the report to your email again.

The crisis has triggered the need for meaningful partnerships within pharma to speed up R&D and become future ready  

Pharmaceuticals firms are facing disruptions across the value chain – with existing clinical trials, manufacturing operations, supply chain, and commercial operations - that may have a profound and lasting impact on some of their business models and operations going forward.

 

 

Related reading

The Emerging Trends of Microneedles for Insulin Delivery

White Paper | 28 Feb 2023

Metaverse in Healthcare: Realizing Business Value and Opportunities

White Paper | 18 Jan 2023

Human Sensing - Enhancing the agility of pharma value chain

White Paper | 18 Jan 2023

How the World Entered the Business of Human Microbiome

White Paper | 14 Nov 2022

Transformation starts here

Integrated ecosystems are key to better patient outcomes.

Talk to our experts

Find out more